ID: ALA5179627

Max Phase: Preclinical

Molecular Formula: C19H19FN2O5

Molecular Weight: 374.37

Representations

Canonical SMILES:  O=C(O)CCNC(=O)[C@@H]1Cc2cc(O)c(O)cc2[C@@H](c2ccc(F)cc2)N1

Standard InChI:  InChI=1S/C19H19FN2O5/c20-12-3-1-10(2-4-12)18-13-9-16(24)15(23)8-11(13)7-14(22-18)19(27)21-6-5-17(25)26/h1-4,8-9,14,18,22-24H,5-7H2,(H,21,27)(H,25,26)/t14-,18+/m0/s1

Standard InChI Key:  VXTOGCNEJGSQMZ-KBXCAEBGSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 374.37

Molecular Weight (Monoisotopic): 374.1278

AlogP: 1.43

#Rotatable Bonds: 5

Polar Surface Area: 118.89

Molecular Species: ACID

HBA: 5

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.58

CX Basic pKa: 6.35

CX LogP: -0.61

CX LogD: -1.46

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.51

Np Likeness Score: -0.06

References

1. Di Sarno V, Giovannelli P, Medina-Peris A, Ciaglia T, Di Donato M, Musella S, Lauro G, Vestuto V, Smaldone G, Di Matteo F, Bifulco G, Castoria G, Migliaccio A, Fernandez-Carvajal A, Campiglia P, Gomez-Monterrey I, Ostacolo C, Bertamino A..  (2022)  New TRPM8 blockers exert anticancer activity over castration-resistant prostate cancer models.,  238  [PMID:35598411] [10.1016/j.ejmech.2022.114435]

Source

Source(1):

• Scientific Literature